Last updated: October 17, 2023
Sponsor: Massachusetts General Hospital
Overall Status: Active - Recruiting
Phase
1
Condition
Venous Thrombosis
Vascular Diseases
Pulmonary Embolism
Treatment
Non-rebreather mask
Oxygen Therapy
Clinical Study ID
NCT05891886
2023P000252
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Adults ≥18 years old
- Confirmed Pulmonary Embolism (PE) on computed tomography pulmonary angiography (CTPA)performed <24 hours prior to enrollment
- Symptom duration <72 hours
- Confirmation of right ventricular dysfunction (RVD) by clinician
- Oxygen saturation ≥90% while breathing room air
Exclusion
Exclusion Criteria:
- Hemodynamic instability
- Use of vasopressors or mechanical circulatory support
- Planned use of thrombolytics or plan for embolectomy
- Oxygen saturation <90% while breathing room air at any time in the EmergencyDepartment (ED)
- New onset arrhythmia
- History of pulmonary hypertension, chronic obstructive pulmonary disease (COPD),hypoventilation syndrome, or congestive heart failure (CHF) with left ventricularejection fraction <40%
- Known pregnancy
- Use of chronic oxygen therapy at baseline
- Vasodilator medication used in the past 24 hours
- Symptom onset ≥72 hours
- Inability to wear a face mask
- Technically inadequate baseline echocardiogram
- Temperature >39° C
- Positive test for Covid-19 or influenza within the previous 10 days
Study Design
Total Participants: 80
Treatment Group(s): 2
Primary Treatment: Non-rebreather mask
Phase: 1
Study Start date:
October 01, 2023
Estimated Completion Date:
June 30, 2027
Study Description
Connect with a study center
Massachusetts General Hospital
Boston, Massachusetts 02114
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.